Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40009630
Localisation
United States of America
Northern America
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
27/04/2023
Statut
Classification
1.5°C
Année cible
2030
AbbVie commits to reduce absolute scope 1 and 2 GHG emissions 42.0% by 2030 from a 2021 base year*. AbbVie also commits to increase active sourcing of renewable electricity from 29.5% in 2021 to 100.0% by 2030. AbbVie further commits that 79.1% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027. * The target boundary includes land-related emissions and removals from bioenergy feedstocks.
Statut
BA1.5 memberDate d'engagement
17/06/2021
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
US00287Y1091
LEI
5493006BTKYVSIO64269
Source : Science Based Targets initiative | Données publiques